The findings represent a "consistent signal suggesting that something is going on with respect to the metabolic, inflammatory, and oxidative profile of some patients that renders them ... particularly susceptible to the therapeutic effects of L-methylfolate as adjunctive therapy above and beyond placebo," Dr. Papakostas said, stressing that confirmatory trials are needed.
These studies were supported by a grant from PamLab. Dr. Papakostas and Dr. Stahl disclosed financial relationships with numerous pharmaceutical companies.